These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 32853672

  • 1. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghadamsiahkali S, Sadr S, Tabarestani M, Pirhayati M, Zendehdel A, Manafi N, Hajiabdolbaghi M, Ahmadinejad Z, Kouchak HE, Jafari S, Khalili H, Salehi M, Seifi A, Golestan FS, Ghiasvand F.
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN, Golmohammadi M, Pourhoseingholi MA, Shokouhi S, Darazam IA.
    Trials; 2020 Jun 03; 21(1):473. PubMed ID: 32493468
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK, Bandyopadhyay A, Singh BC, Moirangthem B, Chikara G, Saha S, Bahurupi YA.
    Trials; 2020 Oct 20; 21(1):866. PubMed ID: 33081849
    [Abstract] [Full Text] [Related]

  • 7. A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, Sancho-López A, Mills-Sánchez P, Centeno-Soto GA, Blanco-Alonso S, Javaloyes-Garachana L, Galán-Gómez A, Valencia-Alijo Á, Gómez-Irusta J, Payares-Herrera C, Morrás-Torre I, Sánchez-Chica E, Delgado-Téllez-de-Cepeda L, Callejas-Díaz A, Ramos-Martínez A, Múñez-Rubio E, Avendaño-Solá C.
    Antimicrob Agents Chemother; 2020 Aug 20; 64(9):. PubMed ID: 32571831
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I, Hatami F, Rabiei MM, Pourhoseingholi MA, Moradi O, Shokouhi S, Hajesmaeili MR, Shabani M, Irvani SSN.
    Trials; 2020 Oct 26; 21(1):880. PubMed ID: 33106183
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
    Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L, SARI-RAF Study Group, SARI-RAF Study Group members.
    Ann Rheum Dis; 2020 Oct 26; 79(10):1277-1285. PubMed ID: 32620597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
    Cheng CY, Lee YL, Chen CP, Lin YC, Liu CE, Liao CH, Cheng SH.
    J Microbiol Immunol Infect; 2020 Jun 26; 53(3):488-492. PubMed ID: 32331982
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rangberg A, Jonassen CM, Omland T, Røsjø H, Dalgard O.
    Trials; 2020 Jun 05; 21(1):485. PubMed ID: 32503662
    [Abstract] [Full Text] [Related]

  • 19. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F, Waldauf P, Halačová M, Zvoníček V, Bala J, Balík M, Beneš J, Klementová O, Kozáková I, Kubricht V, Le Roy A, Vymazal T, Řehořová V, Černý V, Czech Anaesthesia Clinical Trials and Audit Network.
    Trials; 2020 Jul 08; 21(1):631. PubMed ID: 32641163
    [Abstract] [Full Text] [Related]

  • 20. Treatment options for COVID-19: The reality and challenges.
    Jean SS, Lee PI, Hsueh PR.
    J Microbiol Immunol Infect; 2020 Jun 08; 53(3):436-443. PubMed ID: 32307245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.